Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy

Since the World Health Organization (WHO) announced coronavirus 2019 (COVID-19) as a pandemic in March 2020, it has been wreaking havoc across countries, affecting people’s lives. Corticosteroids have proven to provide a mortality benefit in patients with COVID-19. Although dexamethasone is the most...

Full description

Saved in:
Bibliographic Details
Main Authors: William Lim, Frederick Lim
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2021/5856600
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850159721959391232
author William Lim
Frederick Lim
author_facet William Lim
Frederick Lim
author_sort William Lim
collection DOAJ
description Since the World Health Organization (WHO) announced coronavirus 2019 (COVID-19) as a pandemic in March 2020, it has been wreaking havoc across countries, affecting people’s lives. Corticosteroids have proven to provide a mortality benefit in patients with COVID-19. Although dexamethasone is the most commonly used glucocorticoid and have shown to have mortality benefit in COVID-19 patients, it cannot be used in patients with adrenal insufficiency due to its lack of mineralocorticoid activity. Herein, we discuss a case of challenging corticosteroid management in a patient with COVID-19 complicated by her medical history of bilateral adrenalectomy.
format Article
id doaj-art-b31b1e06f0734ca18da46db6d6e0e62f
institution OA Journals
issn 2090-6625
2090-6633
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Case Reports in Infectious Diseases
spelling doaj-art-b31b1e06f0734ca18da46db6d6e0e62f2025-08-20T02:23:26ZengWileyCase Reports in Infectious Diseases2090-66252090-66332021-01-01202110.1155/2021/58566005856600Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral AdrenalectomyWilliam Lim0Frederick Lim1Department of Internal Medicine, Richmond University Medical Center, Staten Island, NY, USADepartment of Endocrinology/Internal Medicine, Prisma Health, Columbia, SC, USASince the World Health Organization (WHO) announced coronavirus 2019 (COVID-19) as a pandemic in March 2020, it has been wreaking havoc across countries, affecting people’s lives. Corticosteroids have proven to provide a mortality benefit in patients with COVID-19. Although dexamethasone is the most commonly used glucocorticoid and have shown to have mortality benefit in COVID-19 patients, it cannot be used in patients with adrenal insufficiency due to its lack of mineralocorticoid activity. Herein, we discuss a case of challenging corticosteroid management in a patient with COVID-19 complicated by her medical history of bilateral adrenalectomy.http://dx.doi.org/10.1155/2021/5856600
spellingShingle William Lim
Frederick Lim
Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
Case Reports in Infectious Diseases
title Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
title_full Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
title_fullStr Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
title_full_unstemmed Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
title_short Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy
title_sort corticosteroid management of coronavirus 2019 covid 19 in patients with bilateral adrenalectomy
url http://dx.doi.org/10.1155/2021/5856600
work_keys_str_mv AT williamlim corticosteroidmanagementofcoronavirus2019covid19inpatientswithbilateraladrenalectomy
AT fredericklim corticosteroidmanagementofcoronavirus2019covid19inpatientswithbilateraladrenalectomy